Midatech Pharma plc MTP
Set alert
As of Mar 24, 3:59 PM ET
52-week range unavailable
- Open
- 0.35
- Prev close
- 0.2851
- Mkt cap
- 1.98M
- Vol
- 164.36K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.2851
- High
- 0.35
- Forward P/E
- 0.00
- Beta
- 1.22
- Short ratio
- 2.12
- Inst. own
- 23.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.50
- 200-d avg
- 6.83
- 1y target
- 0.00
Key statistics
- Market cap
- 1.98M
- Enterprise value
- -5.25M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 3.06
- Price / book
- 0.04
- EPS (TTM)
- -2.06
- Beta
- 1.22
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 645.00K
- Revenue growth
- 16.70%
- Free cash flow
- -6.02M
- Total cash
- 6.42M
- Total debt
- 713.00K
- Return on equity
- -95.47%
- Shares outstanding
- 6.93M
- Short % of float
- 0.00%
- 50-day average
- 1.50
- 200-day average
- 6.83
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
About Midatech Pharma plc
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- midatechpharma.com
News
- Pecoy Copper Defines Large Untested MTP-01 Target Beyond Newly Expanded Northwest Copper Mineralization
- MTP Joins Real, Launches Midwest Top Producers Brand
- Italy's banking shake-up: all the M&A deals since 2025
- Why Is Midatech Pharma (BDRX) Stock Up 64% Today?
- Stocks That Hit 52-Week Lows On Friday
- Midatech Pharma plc continues to plummet on news of London delisting
- Stocks That Hit 52-Week Lows On Monday
- Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
- Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday
- Midatech Pharma boosted by European news on key product
Your note
Sign in to keep a note on MTP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Armistice Capital LLC | — | Sold | May 28, 2020 | 36,118 |
| Bank of America Corporation | — | Decrease | Jul 29, 2020 | 4,810 |
| Goldman Sachs Group, Inc. | — | Holding | Aug 5, 2020 | 1,500 |
| L1 Global Manager Pty, Ltd. | — | Sold | May 18, 2020 | 25,181 |
| Lind Partners, L.L.C. | — | Sold | May 25, 2020 | 60,040 |
| Lombard Odier Asset Management (Europe) Ltd | — | Holding | Jul 5, 2021 | 295,500 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 0.00% | 96,707 | 27.57K | Dec 30, 2022 |
| Renaissance Technologies, LLC | 0.00% | 8,867 | 2.53K | Dec 30, 2022 |
| Morgan Stanley | 0.00% | 3,924 | 1.12K | Dec 30, 2022 |
| Money Concepts Capital Corporation | 0.00% | 69 | 19 | Dec 30, 2022 |
| UBS Group AG | 0.00% | 31 | 8 | Dec 30, 2022 |
| Group One Trading, L.P. | 0.00% | 1 | 0 | Dec 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.01% | 1,479 | 421 | Nov 29, 2022 |